Clinical Trial Update: A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating Efimosfermin Alfa in participants with biopsy-confirmed compensated cirrhosis due to Metabolic Dysfunction-Associated Steatohepatitis…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Liver Cirrhosis
• Metabolic Dysfunction-associated Steatohepatitis

Drugs mentioned

• Efimosfermin Alfa (efimosfermin alfa)

Snippet

Sponsor: Boston Pharmaceuticals | Conditions: Metabolic Dysfunction-Associated Steatohepatitis | Phase 2 | Status: RECRUITING